Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 2 of 2 entries
Sorted by: Best Match Show Resources per page
Diagnosis of acquired generalized lipodystrophy in a single patient with T-cell lymphoma and no exposure to Metreleptin.

Clinical diabetes and endocrinology

Esfandiari NH, Rubenfire M, Neidert AH, Hench R, Eldin AJ, Meral R, Oral EA.
PMID: 30923630
Clin Diabetes Endocrinol. 2019 Mar 14;5:4. doi: 10.1186/s40842-019-0076-9. eCollection 2019.

BACKGROUND: Metreleptin, a recombinant methionyl -human -leptin, was approved to treat patients with generalized lipodystrophy (GL) in February 2014. However, leptin therapy has been associated with the development of lymphoma. We present a unique case of a patient with...

Cite
Esfandiari NH, Rubenfire M, Neidert AH, et al. Diagnosis of acquired generalized lipodystrophy in a single patient with T-cell lymphoma and no exposure to Metreleptin. Clin Diabetes Endocrinol. 2019;5:4doi: 10.1186/s40842-019-0076-9.
Esfandiari, N. H., Rubenfire, M., Neidert, A. H., Hench, R., Eldin, A. J., Meral, R., & Oral, E. A. (2019). Diagnosis of acquired generalized lipodystrophy in a single patient with T-cell lymphoma and no exposure to Metreleptin. Clinical diabetes and endocrinology, 54. https://doi.org/10.1186/s40842-019-0076-9
Esfandiari, Nazanene H, et al. "Diagnosis of acquired generalized lipodystrophy in a single patient with T-cell lymphoma and no exposure to Metreleptin." Clinical diabetes and endocrinology vol. 5 (2019): 4. doi: https://doi.org/10.1186/s40842-019-0076-9
Esfandiari NH, Rubenfire M, Neidert AH, Hench R, Eldin AJ, Meral R, Oral EA. Diagnosis of acquired generalized lipodystrophy in a single patient with T-cell lymphoma and no exposure to Metreleptin. Clin Diabetes Endocrinol. 2019 Mar 14;5:4. doi: 10.1186/s40842-019-0076-9. eCollection 2019. PMID: 30923630; PMCID: PMC6419468.
Copy Download .nbib Format: NLM
Efficacy and Safety of Metreleptin in Patients with Partial Lipodystrophy: Lessons from an Expanded Access Program.

Journal of diabetes & metabolism

Ajluni N, Dar M, Xu J, Neidert AH, Oral EA.
PMID: 27642538
J Diabetes Metab. 2016 Mar;7(3). doi: 10.4172/2155-6156.1000659. Epub 2016 Mar 23.

OBJECTIVE: Patients with lipodystrophy have severe metabolic abnormalities (insulin resistance, diabetes, and hypertriglyceridemia) that may increase morbidity and mortality. Metreleptin is approved by the United States Food and Drug Administration for treatment of generalized forms of lipodystrophy. We aimed...

Cite
Ajluni N, Dar M, Xu J, et al. Efficacy and Safety of Metreleptin in Patients with Partial Lipodystrophy: Lessons from an Expanded Access Program. J Diabetes Metab. 2016;7(3)doi: 10.4172/2155-6156.1000659.
Ajluni, N., Dar, M., Xu, J., Neidert, A. H., & Oral, E. A. (2016). Efficacy and Safety of Metreleptin in Patients with Partial Lipodystrophy: Lessons from an Expanded Access Program. Journal of diabetes & metabolism, 7(3), . https://doi.org/10.4172/2155-6156.1000659
Ajluni, Nevin, et al. "Efficacy and Safety of Metreleptin in Patients with Partial Lipodystrophy: Lessons from an Expanded Access Program." Journal of diabetes & metabolism vol. 7,3 (2016). doi: https://doi.org/10.4172/2155-6156.1000659
Ajluni N, Dar M, Xu J, Neidert AH, Oral EA. Efficacy and Safety of Metreleptin in Patients with Partial Lipodystrophy: Lessons from an Expanded Access Program. J Diabetes Metab. 2016 Mar;7(3). doi: 10.4172/2155-6156.1000659. Epub 2016 Mar 23. PMID: 27642538; PMCID: PMC5026130.
Copy Download .nbib Format: NLM
Showing 1 to 2 of 2 entries